Brief: CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials
March 15 (Reuters) - CytRx Corp CYTR.O :
* CYTRX SELECTS FOUR NEW LADR™ ULTRA HIGH POTENCY DRUG
CANDIDATES
FOR ADVANCEMENT TOWARD CLINICAL TRIALS
* CYTRX - ALL FOUR CANDIDATES ARE ELIGIBLE TO ADVANCE INTO
IND
-ENABLING STUDIES, GOAL OF FILING IND APPLICATIONS ON ONE/MORE
CANDIDATES IN 2018
Source text for Eikon: ID:nPn1BzZM6a
Further company coverage: CYTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C